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Introduction
Recently, the “American Association of Oral and 
Maxillofacial Surgeons” (AAOMS) proposed to change 
the term “bisphosphonates-related osteonecrosis of the 
jaws” (BRONJ) into “medication-related osteonecrosis 
of the jaws” (MRONJ) based on the growing number 
of its clinical cases involving the maxilla and mandible 
associated with other anti-resorption (denosumab) and 
anti-angiogenic drugs.1 The diagnosis for MRONJ, based 
also on radiological and serological (CTX) data, does not 
yet give a clear indication for the treatment protocol.2-4
A recent review of the literature has well exposed that 
the scientific community has not found a viable solution 
to counter this challenging disease,5 and the emphasis 
that has been placed by the AAOMS on the preventive 
aspects for this disease, unmasks the current uncertainty 
regarding the therapeutic approach.
Although there is no consensus on a resolving therapy 
for this disease, surgery plays a key role: the results for 
the surgical approach appear to be better than that of the 
conservative one.6
These drugs create some alteration in bone homeostasis 
by the alteration of the bone turnover balance and the 
angiogenic pathway.
This disease implications are particularly insidious for 
several reasons:
(a) The mechanism by which it achieves bone necrosis 
is not clear, it is often (about 60% of cases) apparently 
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Abstract
Introduction: The proper therapeutic plan for medication-related osteonecrosis of the Jaw (MRONJ) 
is still lacking long-term data up to today. They were several high-technological appliances proposed 
for the different intervention steps, in addition to tissue repair promoters. The reason for proposing 
an integrated technique is justified, beyond better compliance of the patients associated to the 
pain and inflammation reduction and bleeding control, there is also achieving better hard and soft 
tissues healing.
Methods: Patients diagnosed with bisphosphonates-related osteonecrosis of the jaws (BRONJ) at 
the Odontostomatology and Maxillo-Facial Surgery Unit of the Hospital of Piacenza undergone 
surgical intervention. The intervention was performed by using different devices: Piezosurgery for 
removing the necrotic bone tissue and for obtaining the bone specimen essential for histological 
analysis; Er:YAG laser (2940 nm) to vaporize necrotic hard tissue until reaching the bleeding bone; 
platelet-rich plasma (PRP) to stimulate hard and soft tissue healing; and finally diode laser (808 nm) 
to perform a biostimulation of the surgical site. 
Results: All treated patients demonstrated a good postoperative comfort even without using 
painkillers, no bleeding, and a fast healing process. Most of the patients (92.85%) reached complete 
healing with a minimum follow up at 6 months. Histological exams demonstrated a good quality 
without artifacts. 
Conclusion: Sequential utilization of different high-technologies devices during all the steps of 
MRONJ treatment allows to perform a faster and less invasive surgery with a more comfortable 
postoperative healing process and it may represent a new and original approach for treating this 
severe adverse event.
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spontaneous, while in the rest of the cases it is related to 
dental procedures and so not classified as an acute event7;
(b) These drugs, particularly bisphosphonates (BFs), 
may remain bioavailable for several years, their action 
persisting a long time after therapy and/or recurring even 
years after the treatment8;
(c) Drugs holiday does not significantly improve the state 
of necrosis even if this strategy is considered as a prudent 
approach by different scientific societies9;
(d) The presence of compromised teeth, as well as the 
surgical act of their removal, can trigger the disease;
(e) Otherwise, it is different from osteoradionecrosis, 
where bleeding bone is the sign of viable bone, in MRONJ 
this is not guaranteed of healthy tissue; this has led 
several authors to recommend a conservative approach in 
treating MRONJ10;
(f) The imbalance of bone cell turnover in osteoblastic 
activity seems to be an imbalance of the whole bone 
extracellular matrix, although there is no consensus on 
this11;
(g) Although the histology of the intraoral soft tissues 
appears normal,12 these drugs also create some changes 
in the epithelium, so determining a deterioration of its 
quality.13-15
If the disease is diagnosed in the early stage and systemic 
conditions are good, the curettage may be successful; 
in advanced cases with severe systemic disease, a more 
invasive approach with the use of free micro-vascularized 
flap with fibula or iliac crest may be necessary.16
In the past years, bone marrow stem cells (BMSCs) have 
been proposed to promote healing of osteonecrotic sites,17 
due to their ability to differentiate into different human 
tissues, revealing a promising therapeutic option in 
different fields of application.
The BMSC are multipotent stem cells (MSCs) able to 
differentiate into different human tissues and bone 
marrow represents a rich bank.18,19
The BMSC belong to the category of MSCs which, 
together with those of adipocytes and umbilical cord, may 
differentiate into different mature tissues (bone marrow, 
cartilage, adipose tissue, muscle, nerve).
MSCs are found widely in the human body, especially in 
organs with high cell turnover (skin, epithelium) and they 
reside in niches that are 3-D micro-environments where 
they participate in tissue homeostasis.
The mechanism by which stem cells (MSC) localize 
themselves is still not well defined.
Very few MSC were found circulating in the peripheral 
blood, and when injected, they have little capacity to 
localize themselves in normal conditions.
The difference of results between orthopedics and 
maxillofacial surgery use of BMSC is linked to the 
different quality of the surrounding tissues.
Literature proposed, as an adjuvant therapy for different 
bone diseases, platelet-rich plasma (PRP) which is largely 
used in maxillofacial surgery20-22 and in many other 
medical fields. The rationale for its use is the addition of 
growth factors (GFs) in suffering environments. PRP, in 
fact, contains many GFs such as fibroblast growth factor 
(FGF), epidermal growth factor (EGF), keratinocyte 
growth factor (KGF), platelet-derived growth factor 
(PDGF), insulin-like growth factor (IGF), vascular 
endothelial growth factor (VEGF), also transforming 
growth factor-β (TGF-β) which may modulate and prevent 
excessive recruitment of inflammatory leukocytes. 
The secretion of these factors starts with platelet activation 
immediately after the addition of calcium which is the co-
factor necessary for the degranulation.23
VEGF is a pleiotropic factor that activates a cascade of 
events inducing the revascularization of injured tissues.24
These proteins are involved in tissue healing through 
cells chemotaxis, proliferation and differentiation, 
angiogenesis and deposition of new extracellular matrix.
Reduced secretion of VEGF caused by the BF may explain 
the difficulty of reparation of intraoral soft tissues.13,25
The PRP has been shown to increase the number of BMSC 
to 4 times as much when administered together, thus 
assuming a role in potentiating the effects of BMSC.26,27 
Although leukocytes have been proposed as additional 
carriers of cytokines and microbicide proteins,28 the 
addition of the leukocytes to the PRP (PRP-L) did not 
demonstrate a difference in the bactericidal power, while 
platelet-derived peptides have shown a role as activators 
of neutrophils.29
This property has been used to reduce the intra-operative 
(short therapy), to boost and eliminate the daily post-
operative administration of antibiotics, and despite the 
dehiscence of the surgical wound, the latter phenomenon 
was almost constant.
Piezosurgery
“Piezosurgery Medical Device” (PMD) is an original 
surgical appliance which uses piezoelectric ultrasonic 
vibrations for cutting, successfully employed for 
performing different bone surgical procedures in the oral 
and maxillofacial field with great results in term of the 
related complications reductions. Its main advantages 
described are the scanty bleeding and bruising, the 
harmless effect on soft tissues and the low pressure 
needed to create bony cuts, so minimizing tissue trauma 
and, consequently, its associated morbidity.30,31 
In the literature, a large case series suggested that bone 
resection performed by a high-power ultrasonic surgery 
associated with antibiotic therapy might lead to BRONJ 
healing.32
Laser
Laser devices are described as useful tools for different 
applications in the treatment of MRONJ, being able to 
perform the removal of necrotic bone by vaporization as 
well as biomodulation of both soft and hard tissues.33,34 
Thanks to the affinity of the Er:YAG laser wavelength 
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(2940 nm) to water and hydroxyapatite, laser technology 
allows for efficient ablation of hard tissues without the 
risk of thermal increase determining necrotic effects on 
tissues. Moreover, even if the classical optical window 
to perform biomodulating effect is in the range of 600-
1000 nm of wavelength, there are some papers describing 
biomodulating effect also for 2940 nm wavelength.35,36
Er:YAG laser, thanks to the respect of tissue in terms of 
thermal increase and also to the biomodulating reported 
properties, is described as linked to a faster bone healing.37
Bone healing is a proliferative physiological process 
determined by several phases and different types of 
tissues (periosteum, endosteum, bone marrow, blood 
vessels) and cells (fibroblasts, chondroblasts, osteoblasts, 
and osteoclasts).38
The main effects of laser application in low-level laser 
therapy (LLLT) protocols on bone tissues seem to 
be related to the increase of bone nodule formation, 
blood vessels, alkaline-phosphatase (ALP) activity and 
osteoblastic activity, DNA synthesis, and of osteoblasts 
differentiation.39-43
LLLT stimulates cells proliferation by the induction 
of cell-cycle regulatory proteins and its capacity of 
favoring the “in vitro” differentiation of satellite cells was 
demonstrated. Particularly, the induction of the mytogen-
activated protein kinase/extracellular signal-regulated 
protein kinase (MAPK-ERK) phosphorylation was 
observed following LLLT irradiation.44 
The mechanism involved in the laser-induced bone repair 
is a two-steps sequence: the first, most likely related to the 
osteoblasts activation for bone matrix production, the 
second, subsequently, for osteoblast activity decrease and 
for osteoclast activity stimulation with the final result to 
promote resorption and remodeling of bone. 
LLLT seems to be more effective for the bone formation 
at an earlier stage instead of at a later stage, due to that 
in the bone healing first step, the cellular component is 
more important, so being more susceptible to the laser 
action. Moreover, because the bone matrix is the main 
component of the healing tissue, a great number of cells 
are in the bone matrix, which incorporates carbonate 
substituted hydroxyapatite (CHA).45,46
The association of Er:YAG laser bone ablation with 
Nd:YAG/diode laser bone biostimulation has been 
already reported as a successful treatment of BRONJ, 
supporting this kind of approach, minimally invasive and 
biostimulative.33,34,47 
The aim of this work is to present the experience of the 
Odontostomatology and Maxillo-Facial Surgery Unit 
of the Hospital of Piacenza (Italy) with a combined 
approach, based on the use of laser, piezosurgery and PRP, 
for the treatment of MRONJ. 
Methods
Patients 
Out of the patients evaluated at the Odontostomatology 
Figure 1. Stage III Left Maxillary Bone Necrosis With Sinus Involvement 
in a 73 Years-Old Woman Treated With Alendronate for Osteoporosis.
and Maxillo-Facial Surgery Unit - Special care dentistry 
of the Guglielmo da Saliceto Hospital of Piacenza (Italy) 
and identified as positive for MRONJ on the basis of 
recognized criteria,1,2 21 patients, 16 women and 5 men 
with a mean age of 72.6 years (range 60-85 years) have 
been treated with a combined surgical approach, after 
the signature of the informed consent. Eleven patients 
(52.4%) were positive for treatment with zoledronate 
for solid tumors (7 for breast cancer), while 10 patients 
(47.6%) were positive for osteometabolic diseases (8 
osteoporosis, 1 rheumatoid arthritis and 1 osteoporosis 
and rheumatoid arthritis) and treatment with oral BPs; 
the duration of treatment with BPs was variable between 5 
and 164 months. Out of oncological patients, 3 have been 
also treated with sunitinib (Table 1). 
Fifteen patients (71.4%) presented a mandibular 
localization for MRONJ, 6 (28.6%) a maxillar localization 
(Figure 1). Based on AAOMS staging system, 2 MRONJ 
(9.6%) were classified as Stage I, 15 MRONJ (71.4%) were 
classified as Stage II and 4 (19%) as Stage III.
The extension and the features of the osteonecrosis were 
evaluated by clinical examination and radiographically 
with panoramic X-rays scan and CT scan.
To all the patients it was prescribed an antibiotic therapy 
with amoxicillin+clavulanate 2 g/d and metronidazole 500 
mg/d per os (or clindamycin in case of allergy), starting 
the therapy 3 days before surgery and interrupting the 
antibiotics at least 2 weeks after surgery and with a closed 
surgical wound.
Piezosurgery
PMD (Mectron, Italy) was applied to remove necrotic 
bone specimen of MRONJ sites allowing a histological 
analysis to finalize the diagnostic confirmation for 
MRONJ (Figures 2A-2B).
The instrument was used with a microsaw of 0.55 mm 
firmly moved over the bone avoiding the use of an 
excessive force and with an integrated saline coolant spray 
to maintain a low temperature and a good vision of the 
surgical site.
Laser Devices
Er:YAG laser device (2940 nm – Lightwalker, Fotona, 
Slovenia) was used in the treated patients to perform 
vaporization of necrotic bone until the observation of 
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bleeding, considering that as a sign of viable, non-MRONJ 
affected bone (Figure 2C). Er:YAG laser was used with a 
mirror handpiece for non-contact application (R02) at 
a distance of about 0.8 cm corresponding to the same 
incidence on tissue for laser light and air-water spray with 
an energy of 200 mJ and a frequency of 20 Hz in Medium 
Short Pulse (Fluence/pulse: 39.80 J/cm2).
Diode laser 808 nm is a laser useful as a surgical 
device on soft tissues but also for biomodulation 
protocols depending on the parameters. It was used to 
perform biomodulating effect both intraoperative and 
postoperatively. The first session was performed just 
after suturing, while the subsequent ones were 2 times/
week until suture removal on a completely closed surgical 
wound. Biomodulation was done with a 600 µm diameter 
fiber in scanning mode on the surgical site with 1 W of 
power in continuous mode during 1 minute for 5 times 
(Theoretical fluence: 21231 J/cm2).
Platelet Rich Plasma 
Autologous platelet gel was prepared at the Department 
of Oncology and Hematology of the Hospital of Piacenza 
(Italy) during the planning of the surgery and stored until 
the day of the intervention. Multiple samples of whole 
blood were obtained from each patient and collected in 10 
mL vacutainers. Blood was then centrifuged at 180 rpm 
per 10 to separate concentrated erythrocytes from PRP 
and then PRP was stored at -40°C.
The day of the surgery, PRP was maintained at room 
temperature until the use and just before that thrombin 
and calcium gluconate were added for platelets activation 
and gelling process acceleration.
PRP gel was used for each patient directly on the wound, 
absorbed on fibrin sponge or injected with a syringe after 
suture directly in the wound (Figures 2D-2E).
Results 
Mean follow-up was 9.6 months. All the 21 patients (100%) 
experienced improvement of MRONJ with a transition 
to a lower stage of the Ruggero classification. Complete 
recovery was observed in 20 out of 21 patients (95.23%) 
(Figure 2F); one patient with mandibular BRONJ in 
Stage 3 and treated with the combined approach, healed 
completely and maintained the healing for 9 months then 
showed a recurrence of MRONJ on the site of intervention. 
All patients described a good post-operative comfort, not 
needing painkillers and reported the absence of bleeding 
and a rapid healing time. The histological evaluations 
performed demonstrated samples of good quality and 
without artifacts, allowing the confirmation of the clinical 
diagnosis (Table 2).
Discussion
Management of MRONJ is still a challenge for oral and 
maxillo-facial surgeons, particularly in relation with new 
anti-angiogenetic drugs as denosumab and sunitinib. 
Guidelines are today in agreement with the use of medical 
approach with antibiotics in all the cases, from Stage I to 
Stage III, in association or not with the surgical approach.48 
In our experience, as reported elsewhere in the literature,49 
an early surgical approach performed in Stage I MRONJ 
maybe efficient for the obtaining a complete healing with 
a minimally invasive surgical approach.
Er:YAG laser may represent a useful option in terms of 
reduction of invasiveness: in fact its wavelength allows 
the vaporization of necrotic bone with good control 
of bone removal because of its affinity for water and 
hydroxyapatite allowing a superficial action; in addition 
to affinity properties, the use of a handpiece with an air-
water spray limits damages the tissue avoiding temperature 
increase at bone level in surgical site and with this thermal 
necrosis.50 These aspects are related to a good comfort 
during and after surgery for the patient with a reduction 
of postsurgical morbidity (with a reduction/elimination 
of pain and edema) and a better and faster healing.51 
Aoki et al reported that Er:YAG laser used for bone surgery 
even with high-level irradiation may induce cell reactions, 
thanks to the scattering phenomena surrounding the 
Figure 2. (A) Removal of Bone Sequestrum. (B) Osteotomy Performed With the Piezosurgical Device. (C) Bone Bleeding After Vaporization With 
Er:YAG Laser. (D) Placement of Gelatinous PRP. (E) Suture With PRP on Site. (F) Complete Healing at 6 Months Follow up.
D E F
A B C
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tissue irradiated, stimulating bone regeneration.52 
Ninomiya et al reported a lower number of osteoclasts 
after pulsed laser irradiation as well as the activation of 
osteoblasts with increased bone formation.53 
Pourzarandian et al reported a faster growth of cultures 
cells irradiated with an Er:YAG laser when compared with 
untreated groups thanks to the stimulation of gingival 
fibroblasts proliferation associated to an earlier mitosis 
and collagen fibril strands increment.35
In the combined treatment we performed on these 
patients, beyond the biostimulating effect of Er:YAG 
laser, we used a biomodulating approach with a diode 
laser (808 nm): this kind of approach, completely safe 
and comfortable for the patient, may help tissue healing 
through the stimulation of keratinocytes, osteoblasts and 
endothelial cells.54
The basis for the use of PRP is the addition of GFs as 
FGF, EGF, KGF, IGF, PDGF, transforming VEGF and 
TGF-β in suffering environments as bone exposed to 
the action of BFs and monoclonal antibodies; in this 
way, after the surgical ablation of necrotic bone and the 
decontamination of the surgical site, PRP may have the 
main role to induce tissue healing by cells chemotaxis, 
proliferation and differentiation, angiogenesis and 
deposition of new extracellular matrix.22
Sequential utilization of different high-technologies 
devices during all the steps of MRONJ treatment allows 
to perform a faster and less invasive surgery with a more 
comfortable postoperative healing process and it may 
represent a new and original approach for treating this 
severe adverse event.
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